1	Tumor	Tumor	B-NP	NN	O	3	NMOD	-1
2	endothelial	endothelial	I-NP	JJ	O	3	NMOD	-1
3	cell	cell	I-NP	NN	O	4	SUB	-1
4	targeted	target	B-VP	VBD	O	0	ROOT	19	targeted
5	cyclic	cyclic	B-NP	JJ	O	8	NMOD	-1
6	RGD-modified	RGD-modified	I-NP	JJ	O	8	NMOD	-1
7	heparin	heparin	I-NP	NN	O	8	NMOD	-1
8	derivative	derivative	I-NP	NN	O	4	OBJ	-1
9	:	:	O	:	O	4	P	-1
10	inhibition	inhibition	B-NP	NN	O	4	VMOD	18	inhibition
11	of	of	B-PP	IN	O	10	NMOD	-1
12	angiogenesis	angiogenesis	B-NP	NN	O	15	NMOD	3	angiogenesis
13	and	and	I-NP	CC	O	15	NMOD	-1
14	tumor	tumor	I-NP	NN	O	15	NMOD	-1
15	growth	growth	I-NP	NN	O	11	PMOD	4	growth
16	.	.	O	.	O	4	P	-1

1	PURPOSE	PURPOSE	B-NP	NN	O	4	SUB	-1
2	:	:	O	:	O	4	P	-1
3	We	We	B-NP	PRP	O	4	SUB	-1
4	prepared	prepare	B-VP	VBD	O	0	ROOT	-1
5	tumor	tumor	B-NP	NN	O	6	NMOD	-1
6	endothelium	endothelium	I-NP	NN	O	7	SUB	-1
7	targeted	target	B-VP	VBD	O	4	VMOD	19	targeted
8	cRGD-modified	cRGD-modified	B-NP	JJ	O	10	NMOD	-1
9	heparin	heparin	I-NP	NN	O	10	NMOD	-1
10	derivative	derivative	I-NP	NN	O	7	OBJ	-1
11	(	(	O	(	O	13	DEP	-1
12	cRGD-HL	cRGD-HL	B-NP	NN	O	13	DEP	-1
13	)	)	O	)	O	10	NMOD	-1
14	by	by	B-PP	IN	O	7	VMOD	-1
15	coupling	couple	B-VP	VBG	O	14	PMOD	-1
16	heparin-lithocholic	heparin-lithocholic	B-NP	JJ	O	17	NMOD	-1
17	acid	acid	I-NP	NN	O	15	OBJ	-1
18	(	(	O	(	O	20	DEP	-1
19	HL	HL	B-NP	NN	O	20	DEP	-1
20	)	)	O	)	O	17	NMOD	-1
21	with	with	B-PP	IN	O	17	NMOD	-1
22	cRGDyK	cRGDyK	B-NP	NN	B-protein	21	PMOD	-1
23	,	,	O	,	O	27	P	-1
24	and	and	O	CC	O	27	NMOD	-1
25	evaluated	evaluate	B-NP	VBN	O	27	NMOD	-1
26	inhibition	inhibition	I-NP	NN	O	27	NMOD	18	inhibition
27	effects	effect	I-NP	NNS	O	4	VMOD	0
28	of	of	B-PP	IN	O	27	NMOD	-1
29	cRGD-HL	cRGD-HL	B-NP	NN	O	28	PMOD	-1
30	on	on	B-PP	IN	O	27	NMOD	-1
31	angiogenesis	angiogenesis	B-NP	NN	O	34	NMOD	3	angiogenesis
32	and	and	I-NP	CC	O	34	NMOD	-1
33	tumor	tumor	I-NP	NN	O	34	NMOD	-1
34	growth	growth	I-NP	NN	O	30	PMOD	4	growth
35	.	.	O	.	O	4	P	-1

1	METHODS	METHODS	B-NP	NNS	O	11	VMOD	-1
2	:	:	O	:	O	1	P	-1
3	To	To	B-VP	TO	O	4	VMOD	-1
4	evaluate	evaluate	I-VP	VB	O	1	VMOD	-1
5	antiangiogenic	antiangiogenic	B-NP	JJ	O	6	NMOD	3	angiogenic
6	activity	activity	I-NP	NN	O	4	OBJ	18	activity
7	of	of	B-PP	IN	O	6	NMOD	-1
8	cRGD-HL	cRGD-HL	B-NP	NN	O	7	PMOD	-1
9	,	,	O	,	O	11	P	-1
10	we	we	B-NP	PRP	O	11	SUB	-1
11	performed	perform	B-VP	VBD	O	0	ROOT	-1
12	tests	test	B-NP	NNS	O	11	OBJ	-1
13	on	on	B-PP	IN	O	12	NMOD	-1
14	endothelial	endothelial	B-NP	JJ	B-cell_type	16	NMOD	-1
15	cell	cell	I-NP	NN	I-cell_type	16	NMOD	-1
16	adhesion	adhesion	I-NP	NN	O	18	NMOD	15	adhesion
17	and	and	O	CC	O	18	NMOD	-1
18	migration	migration	B-NP	NN	O	26	NMOD	14	migration
19	to	to	B-PP	TO	O	18	NMOD	-1
20	vitronectin	vitronectin	B-NP	NN	B-protein	19	PMOD	-1
21	,	,	O	,	O	26	P	-1
22	tube	tube	B-NP	NN	O	23	NMOD	-1
23	formation	formation	I-NP	NN	O	26	NMOD	2	formation
24	,	,	O	,	O	26	P	-1
25	binding	binding	B-NP	NN	O	26	NMOD	15	binding
26	affinity	affinity	I-NP	NN	O	13	PMOD	0
27	to	to	B-PP	TO	O	26	NMOD	-1
28	purified	purify	B-NP	VBN	B-protein	37	NMOD	0
29	alpha	alpha	I-NP	NN	I-protein	37	NMOD	-1
30	(	(	O	(	I-protein	37	NMOD	-1
31	v	v	B-NP	NN	I-protein	37	NMOD	-1
32	)	)	O	)	I-protein	37	NMOD	-1
33	beta	beta	B-NP	NN	I-protein	37	NMOD	-1
34	(	(	O	(	I-protein	37	NMOD	-1
35	3	3	B-NP	CD	I-protein	37	NMOD	-1
36	)	)	O	)	I-protein	37	NMOD	-1
37	integrin	integrin	B-NP	NN	I-protein	27	PMOD	-1
38	,	,	O	,	O	44	P	-1
39	and	and	O	CC	O	44	NMOD	-1
40	in	in	B-NP	FW	O	41	AMOD	-1
41	vivo	vivo	I-NP	FW	O	44	NMOD	-1
42	Matrigel	Matrigel	I-NP	NNP	O	44	NMOD	-1
43	plug	plug	I-NP	NN	O	44	NMOD	-1
44	assay	assay	I-NP	NN	O	11	VMOD	-1
45	.	.	O	.	O	11	P	-1

1	The	The	B-NP	DT	O	3	NMOD	-1
2	antitumor	antitumor	I-NP	JJ	O	3	NMOD	-1
3	activity	activity	I-NP	NN	O	6	SUB	18	activity
4	of	of	B-PP	IN	O	3	NMOD	-1
5	cRGD-HL	cRGD-HL	B-NP	NN	O	4	PMOD	-1
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	also	also	I-VP	RB	O	6	VMOD	-1
8	evaluated	evaluate	I-VP	VBN	O	6	VC	-1
9	by	by	B-PP	IN	O	8	VMOD	-1
10	monitoring	monitor	B-VP	VBG	O	9	PMOD	-1
11	tumor	tumor	B-NP	NN	O	12	NMOD	-1
12	growth	growth	I-NP	NN	O	15	NMOD	4	growth
13	and	and	O	CC	O	15	NMOD	-1
14	microvessel	microvessel	B-NP	NN	O	15	NMOD	-1
15	formation	formation	I-NP	NN	O	10	OBJ	2	formation
16	in	in	B-PP	IN	O	10	VMOD	-1
17	squamous	squamous	B-NP	JJ	O	19	NMOD	-1
18	cell	cell	I-NP	NN	O	19	NMOD	-1
19	carcinoma	carcinoma	I-NP	NN	O	23	NMOD	-1
20	(	(	O	(	O	22	DEP	-1
21	SCC7	SCC7	B-NP	NN	B-protein	22	DEP	-1
22	)	)	O	)	O	19	NMOD	-1
23	tumor	tumor	B-NP	NN	O	16	PMOD	-1
24	.	.	O	.	O	6	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	4	NMOD	-1
4	cRGD-HL	cRGD-HL	I-NP	NN	O	6	SUB	-1
5	significantly	significantly	B-ADVP	RB	O	6	VMOD	-1
6	inhibited	inhibit	B-VP	VBD	O	18	NMOD	18	inhibited
7	adhesion	adhesion	B-NP	NN	O	9	NMOD	15	adhesion
8	and	and	I-NP	CC	O	9	NMOD	-1
9	migration	migration	I-NP	NN	O	6	OBJ	14	migration
10	of	of	B-PP	IN	O	9	NMOD	-1
11	endothelial	endothelial	B-NP	JJ	B-cell_type	12	NMOD	-1
12	cells	cell	I-NP	NNS	I-cell_type	10	PMOD	-1
13	to	to	B-PP	TO	O	9	NMOD	-1
14	vitronectin	vitronectin	B-NP	NN	B-protein	13	PMOD	-1
15	,	,	O	,	O	18	P	-1
16	and	and	O	CC	O	18	NMOD	-1
17	tubular	tubular	B-NP	JJ	O	18	NMOD	-1
18	structures	structure	I-NP	NNS	O	1	NMOD	-1
19	of	of	B-PP	IN	O	18	NMOD	-1
20	endothelial	endothelial	B-NP	JJ	B-cell_type	21	NMOD	-1
21	cells	cell	I-NP	NNS	I-cell_type	19	PMOD	-1
22	.	.	O	.	O	18	P	-1

1	Compared	Compare	B-PP	VBN	O	8	VMOD	-1
2	to	to	B-PP	TO	O	1	PMOD	-1
3	cRGDyK	cRGDyK	B-NP	NN	B-protein	5	NMOD	-1
4	and	and	I-NP	CC	O	5	NMOD	-1
5	HL	HL	I-NP	NN	O	2	PMOD	-1
6	,	,	O	,	O	8	P	-1
7	cRGD-HL	cRGD-HL	B-NP	NN	O	8	SUB	-1
8	has	have	B-VP	VBZ	O	0	ROOT	-1
9	high	high	B-NP	JJ	O	11	NMOD	-1
10	binding	binding	I-NP	NN	O	11	NMOD	15	binding
11	affinity	affinity	I-NP	NN	O	8	OBJ	0
12	to	to	B-PP	TO	O	11	NMOD	-1
13	purified	purify	B-NP	VBN	B-protein	22	NMOD	0
14	alpha	alpha	I-NP	NN	I-protein	22	NMOD	-1
15	(	(	O	(	I-protein	22	NMOD	-1
16	v	v	B-NP	NN	I-protein	22	NMOD	-1
17	)	)	O	)	I-protein	22	NMOD	-1
18	beta	beta	B-NP	NN	I-protein	22	NMOD	-1
19	(	(	O	(	I-protein	22	NMOD	-1
20	3	3	B-NP	CD	I-protein	22	NMOD	-1
21	)	)	O	)	I-protein	22	NMOD	-1
22	integrin	integrin	B-NP	NN	I-protein	12	PMOD	-1
23	.	.	O	.	O	8	P	-1

1	The	The	B-NP	DT	O	4	NMOD	-1
2	enhanced	enhance	I-NP	VBN	O	4	NMOD	17	enhanced
3	antiangiogenic	antiangiogenic	I-NP	JJ	O	4	NMOD	3	angiogenic
4	effect	effect	I-NP	NN	O	7	SUB	18	effect
5	of	of	B-PP	IN	O	4	NMOD	-1
6	cRGD-HL	cRGD-HL	B-NP	NN	O	5	PMOD	-1
7	was	be	B-VP	VBD	O	0	ROOT	-1
8	confirmed	confirm	I-VP	VBN	O	7	VC	-1
9	in	in	B-PP	IN	O	8	VMOD	-1
10	Matrigel	Matrigel	B-NP	NNP	O	11	NMOD	-1
11	assay	assay	I-NP	NN	O	9	PMOD	-1
12	by	by	B-PP	IN	O	8	VMOD	-1
13	showing	show	B-VP	VBG	O	12	PMOD	-1
14	the	the	B-NP	DT	O	16	NMOD	-1
15	significant	significant	I-NP	JJ	O	16	NMOD	-1
16	inhibition	inhibition	I-NP	NN	O	13	OBJ	18	inhibition
17	of	of	B-PP	IN	O	16	NMOD	-1
18	bFGF-driven	bFGF-driven	B-NP	JJ	O	19	NMOD	17	driven
19	angiogenesis	angiogenesis	I-NP	NN	O	23	NMOD	3	angiogenesis
20	and	and	O	CC	O	23	NMOD	-1
21	blood	blood	B-NP	NN	O	23	NMOD	-1
22	vessel	vessel	I-NP	NN	O	23	NMOD	-1
23	formation	formation	I-NP	NN	O	17	PMOD	2	formation
24	.	.	O	.	O	7	P	-1

1	It	It	B-NP	PRP	O	2	SUB	-1
2	was	be	B-VP	VBD	O	0	ROOT	-1
3	thought	think	I-VP	VBN	O	2	VC	-1
4	that	that	B-SBAR	IN	O	3	VMOD	-1
5	potent	potent	B-NP	JJ	O	7	NMOD	-1
6	antiangiogenic	antiangiogenic	I-NP	JJ	O	7	NMOD	3	angiogenic
7	effect	effect	I-NP	NN	O	10	SUB	18	effect
8	of	of	B-PP	IN	O	7	NMOD	-1
9	cRGD-HL	cRGD-HL	B-NP	NN	O	8	PMOD	-1
10	was	be	B-VP	VBD	O	4	SBAR	-1
11	probably	probably	B-ADVP	RB	O	10	VMOD	-1
12	due	due	B-ADJP	JJ	O	10	PRD	0
13	to	to	B-PP	TO	O	12	AMOD	-1
14	the	the	B-NP	DT	O	15	NMOD	-1
15	interference	interference	I-NP	NN	O	13	PMOD	18	interference
16	of	of	B-PP	IN	O	15	NMOD	-1
17	alpha	alpha	B-NP	NN	O	21	NMOD	-1
18	(	(	O	(	O	20	DEP	-1
19	v	v	B-NP	NN	O	20	DEP	-1
20	)	)	O	)	O	17	NMOD	-1
21	beta	beta	B-NP	NN	O	26	NMOD	-1
22	(	(	O	(	O	26	NMOD	-1
23	3	3	B-NP	CD	O	26	NMOD	-1
24	)	)	O	)	O	26	NMOD	-1
25	-mediated	-mediated	B-NP	JJ	O	26	NMOD	-1
26	interaction	interaction	I-NP	NN	O	16	PMOD	15	interaction
27	,	,	O	,	O	15	P	-1
28	resulting	result	B-VP	VBG	O	15	NMOD	0
29	in	in	B-PP	IN	O	28	VMOD	-1
30	the	the	B-NP	DT	O	33	NMOD	-1
31	enhanced	enhance	I-NP	VBN	O	33	NMOD	17	enhanced
32	antitumoral	antitumoral	I-NP	JJ	O	33	NMOD	-1
33	activity	activity	I-NP	NN	O	29	PMOD	0
34	against	against	B-PP	IN	O	33	NMOD	18	against
35	SCC7	SCC7	B-NP	NN	B-protein	36	NMOD	-1
36	tumor	tumor	I-NP	NN	O	34	PMOD	-1
37	.	.	O	.	O	2	P	-1

1	CONCLUSION	CONCLUSION	B-NP	NN	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	These	These	B-NP	DT	O	4	NMOD	-1
4	results	result	I-NP	NNS	O	5	SUB	0
5	demonstrated	demonstrate	B-VP	VBD	O	1	NMOD	-1
6	that	that	B-SBAR	IN	O	5	VMOD	-1
7	cRGD-modified	cRGD-modified	B-NP	JJ	O	9	NMOD	-1
8	heparin	heparin	I-NP	NN	O	9	NMOD	-1
9	derivative	derivative	I-NP	NN	O	10	SUB	-1
10	enhanced	enhance	B-VP	VBD	O	21	VMOD	17	enhanced
11	anti-angiotherapeutic	anti-angiotherapeutic	B-NP	JJ	O	12	NMOD	3	angiotherapeutic
12	effects	effect	I-NP	NNS	O	10	OBJ	18	effects
13	against	against	B-PP	IN	O	12	NMOD	0
14	solid	solid	B-NP	JJ	O	15	NMOD	-1
15	tumor	tumor	I-NP	NN	O	13	PMOD	-1
16	,	,	O	,	O	21	P	-1
17	and	and	O	CC	O	21	VMOD	-1
18	therefore	therefore	B-ADVP	RB	O	21	VMOD	-1
19	,	,	O	,	O	21	P	-1
20	it	it	B-NP	PRP	O	21	SUB	-1
21	could	could	B-VP	MD	O	6	SBAR	-1
22	be	be	I-VP	VB	O	21	VC	-1
23	applied	apply	I-VP	VBN	O	22	VC	-1
24	to	to	I-VP	TO	O	25	VMOD	-1
25	treat	treat	I-VP	VB	O	23	VMOD	19	treat
26	various	various	B-NP	JJ	O	27	NMOD	-1
27	cancers	cancer	I-NP	NNS	O	30	NMOD	-1
28	and	and	O	CC	O	30	NMOD	-1
29	angiogenic	angiogenic	B-NP	JJ	O	30	NMOD	3	angiogenic
30	diseases	disease	I-NP	NNS	O	25	OBJ	-1
31	as	as	B-PP	IN	O	25	VMOD	-1
32	a	a	B-NP	DT	O	35	NMOD	-1
33	potent	potent	I-NP	JJ	O	35	NMOD	-1
34	angiogenesis	angiogenesis	I-NP	NN	O	35	NMOD	3	angiogenesis
35	inhibitor	inhibitor	I-NP	NN	O	31	PMOD	0
